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Abstract
Background & Aims—The safety profiles of boceprevir and telaprevir in the treatment of 
chronic hepatitis C, administered in academic and community centres across the United States, 
were evaluated.
Methods—In 90 medical centres, patients with chronic HCV received pegylated interferon, 
ribavirin, and either telaprevir or boceprevir per local standard of care. Demographic, adverse 
event, clinical, and virological data were collected during treatment and follow-up.
Results—A total of 2084 patients (97% HCV genotype 1) received at least one dose of a 
protease inhibitor. At baseline, 38% of patients had cirrhosis, and 57% had received at least one 
prior treatment for hepatitis C. Serious adverse events occurred in 12% of patients receiving 
protease inhibitor therapy. Overall, 66% of patients experienced anaemia, leading to frequent 
ribavirin dose reductions (42%) and erythropoietin use (37%); 11% received blood transfusion. 
More than 90% of patients had adverse events that led to a prescription, treatment, or dosage 
change, and 39% of patients discontinued treatment early, most commonly because of adverse 
events (18%) or lack of efficacy (16%). Hepatic decompensation events occurred in 3% of all 
patients. Age, female gender, cirrhosis, HCV genotype 1 subtype, creatinine clearance, platelet 
levels, albumin levels and haemoglobin levels were independent predictors of anaemia. Five 
deaths occurred. Overall, 52% of all patients achieved a sustained virologic response.
Conclusions—In academic and community centres, where chronic hepatitis C patients 
commonly have advanced liver disease, triple therapy was associated with a high rate of adverse 
events and involved frequent treatment modifications and adverse event management.
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Introduction
Following a decade of only modest advances in the treatment of chronic hepatitis C virus 
(HCV), telaprevir and boceprevir, both HCV protease inhibitors, were approved by the FDA 
in 2011 as the first direct-acting antiviral agents (DAAs) to be used in combination with 
pegylated interferon-alfa (PegIFNα) and ribavirin for genotype 1 HCV infection. For 
treatment-naïve patients, the protease inhibitors improved the likelihood of a sustained 
virologic response relative to PegIFNα and ribavirin alone from 40–50% to 67–75% [1–4]. 
The triple therapy regimens involved frequent on-treatment monitoring for response, and the 
addition of the third agent created a new set of adverse events, such as rash and incremental 
anaemia, requiring additional resources for management [5].
The patient population in the real world may differ from that which was reflected in the 
phase 3 registration trials. Whereas the current patient population seen in clinic settings may 
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include a large proportion of older patients with cirrhosis, relatively few patients with 
cirrhosis (all compensated) were included in the registration trials of both boceprevir and 
telaprevir [2,3]. Recently, a large European cohort enrolled a broad clinical patient 
population including those with compromised liver function and reported that the addition of 
a protease inhibitor to PegIFNα and ribavirin increased the likelihood of adverse events, 
many of which were serious and led to premature discontinuation of therapy [6]. Other 
studies reported that the presence of cirrhosis further increased the potential for anaemia [3–
5,7] and hepatic decompensation [2–4,6]. A recent study of patients at tertiary European 
referral centres reported a higher proportion of patients who stopped HCV triple therapy 
than in registration trials [8]. The difference in discontinuation rates was attributed to the 
more frequent occurrences of both virological treatment failure and adverse events. In order 
to provide a more accurate safety profile of the clinical HCV population, we designed and 
executed a cohort study of the safety of triple therapy with boceprevir or telaprevir in 
predominantly genotype 1-infected patients, treated at a consortium of academic and 
community medical centres.
Materials and methods
Study population and design
HCV-TARGET is a longitudinal, observational study in chronic hepatitis C patients from a 
consortium of academic (n = 38) and community (n = 52) medical centres. Patients ≥18 
years old were included if they were being treated or had been treated with antiviral 
regimens containing PegIFNα and ribavirin, in combination with telaprevir or boceprevir. 
Treatment was chosen and administered per local standards at the study site. The study 
protocol did not define specific treatment populations, regimens, dosing, or safety 
management guidelines. Data was captured from sequentially enrolled patients using a 
common database that utilized novel, standardized source data abstraction methods. A 
centralized team of trained coders reviewed all de-identified medical records, obtained from 
participating sites for data entry. Throughout treatment and during post-treatment follow-up, 
demographic, clinical, adverse event, and virological data were collected. Independent data 
monitors systematically reviewed the data entries for completeness and accuracy. All 
records were screened for extreme or unlikely values and verified/resolved with additional 
queries. Data from 337 patients from PEG-BASE-USA, an observational study of 
peginterferon (e.g. Pegasys®)-based direct-acting antiviral triple therapy in patients with 
chronic hepatitis C genotype 1 (NCT01508130), a study funded by Genentech (South San 
Francisco, CA, USA), were mapped to harmonize with the HCV-TARGET database and are 
included in the current analyses. Patients received pegylated interferon alfa-2a or pegylat-ed 
interferon alfa-2b and ribavirin plus either telaprevir or boceprevir in accordance with the 
local standard of care and U.S. labelling and were followed for the duration of their 
treatment and for up to 24 weeks post-treatment.
This study was approved by the local Institutional Review Boards at all participating sites. 
Participants provided written informed consent, or were enrolled under a waiver of consent 
according to local IRB policies.
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Sustained virologic response (SVR)—SVR was defined as HCV RNA below the level 
of quantification (BLOQ) 12 weeks after the end of HCV treatment. Patients lacking a 12-
week post-treatment plasma sample were considered treatment failures.
Cirrhosis—The presence of cirrhosis was defined by biopsy and/or a combination of 
clinical, laboratory, and imaging criteria established a priori. Patients were determined to 
have cirrhosis if they had: (1) evidence of stage 4 fibrosis by liver biopsy at any time prior to 
therapy; or (2) evidence of stage 3 fibrosis by liver biopsy at any time prior to therapy with 
any of the following criteria: platelets count <140,000 per μl, presence of oesophageal 
varices on oesophagogastroduodenoscopy, evidence of cirrhosis and/or portal hypertension 
and/or of ascites by imaging studies, FibroSure test or equivalent, compatible with stage 4 
fibrosis; or (3) in the absence of liver biopsy, any two of the following criteria: platelet count 
<140,000 per μl, presence of oesophageal varices on oesophagogastroduodenoscopy, 
evidence of cirrhosis and/or portal hypertension and/or ascites by imaging studies, FibroSure 
test or equivalent, compatible with stage 4 fibrosis.
Adverse events (AEs)—(1) Any AE that required a prescription medication for 
management, or resulted in a dose reduction or discontinuation of HCV treatment; or (2) any 
adverse event of special interest (rash, dysgeusia, anaemia, anorectal symptoms) regardless 
of treatment prescribed at any time during treatment; that happened at any time during 
treatment or up to 12 weeks after the end of treatment.
Anaemia—Defined as the presence of at least one of the following: (1) anaemia was 
reported as AE by healthcare practitioner; (2) haemoglobin <10 g/dl; or (3) administration of 
RBC growth factors; or (4) transfusion occurred.
Hepatic decompensation during therapy—Patient experienced one or more of the 
following AEs: (1) Hepatic decompensation was listed as an AE by the healthcare 
practitioner; or (2) new onset of hepatic encephalopathy; (3) new onset of spontaneous 
bacterial peritonitis; (4) new onset of variceal haemorrhage; (5) new onset of ascites; (6) 
patient received a new prescription for a medication to treat one of the above indications (1–
5).
Serious adverse event (SAE)—An AE that required hospitalization or met criteria for 
expedited reporting per FDA form MEDWATCH 3500.
Statistical analyses—The rate of treatment completion and frequency of adverse events 
were calculated for the entire study population and for subpopulations of special interest. 
Confidence intervals of the proportions were calculated using exact binomial methods. 
Kaplan-Meier estimates of treatment persistence were constructed in graphical displays, 
using the dates of starting and stopping peginterferon to determine the duration of 
persistence. Multivariable logistic regression models and a stepwise variable selection 
algorithm were used to identify potential baseline risk factors for anaemia in the study 
population. The set of potential variables of interest were selected a priori based upon a 
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consensus of clinical expertise. The model was restricted to HCV genotype 1 patients; 
laboratory values used in the model were baseline measurements. The estimates of the 
stepwise-selected variables were compared with estimates from minimally adjusted model. 
Because some observations were missing values for some baseline variables, the estimated 
odds ratios and confidence intervals of the selected risk factors of the multivariate logistic 
model with stepwise selection were based on the data filled in using multiple imputation 
method. Analyses were performed using SAS software version 9.3 (SAS Institute Inc., Cary, 
North Carolina) and R 3.0.2 (R Core Team, Vienna, Austria).
Results
Patient characteristics
Between May 2011 and June 2013, 2757 patients consented to participate in HCV-TARGET 
and 2122 started therapy prior to September 1, 2012. Of these, 2084 received at least one 
dose of telaprevir or boceprevir and were included in the current safety analysis (Fig. 1). 
Baseline characteristics for all treated patients are shown in Table 1. Seventy nine percent of 
patients were white and 16% were black. Median age was 56 years and 61% of patients were 
male. HCV genotype 1a was reported in 56% and genotype 1b in 23% of patients. Of note, 
an additional 18% of treated patients were genotype 1, although no further subtyping was 
specified. Fifty-seven percent of patients were previously treated with an interferon-
containing regimen.
Cirrhosis was present in 38% of patients (Table 1). Among patients with cirrhosis, mean 
platelet count per μl was 122 × 103, compared to 208 ×103 in non-cirrhotic patients, and a 
mean platelet count of 96 ×103 was observed in cirrhotic patients with a history of hepatic 
decompensation (Supplementary Table 1). The mean albumin level was 3.9 g/dl in cirrhotic 
patients and their mean MELD score was 8.2 (range 6.0–21.0). Oesophageal varices were 
noted on prior endoscopy in 257/485 (53%) cirrhotic patients with available history of 
varices and 47/ 67 (70%) patients with history of hepatic decompensation (Supplementary 
Table 1).
Treatment completion status
Overall, 60% completed a full course of therapy, which included 56% of those treated with 
boceprevir and 61% of those treated with telaprevir. Adverse events and lack of efficacy 
were the leading causes for early discontinuation: 18% of boceprevir patients and 18% of 
telaprevir patients discontinued treatment due to an AE, and 20% of boceprevir patients and 
16% of telaprevir patients stopped treatment due to lack of efficacy. Only 3% of patients 
were lost to follow-up during the treatment phase (Table 2).
Treatment persistence and efficacy
Mean treatment duration (based on interferon treatment first and last dates) was 209 days for 
telaprevir patients and 209 days for boceprevir patients. Treatment persistence estimates 
plotted at various time points are shown in Fig. 2. The period of greatest treatment 
discontinuation was around day 150 of treatment in patients treated with telaprevir and 
around day 90 in patients treated with boceprevir. Forty-four percent (95% CI: 39–49%) of 
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boceprevir patients and 54% (95% CI: 52–57%) of telaprevir patients achieved a sustained 
virologic response (SVR) (Table 2), and overall 43% (95% CI: 40–47%) of patients with 
cirrhosis, treated with DAA-based therapy, were cured (Supplementary Table 1).
Safety
Most patients (95%) experienced an AE (Table 2). Anaemia was observed in two thirds of 
patients, regardless of the DAA used and was the adverse event that most frequently 
required clinical intervention. Haemoglobin decrease to a nadir of <10 g/dl occurred in 
about half of patients treated with either DAA (boceprevir or telaprevir), severe anaemia 
(defined as haemoglobin <8.5 g/dl) developed in about 17%. Plots for changes in 
haemoglobin during the first 24 weeks of therapy are shown in Fig. 3. Anaemia was most 
frequently managed by ribavirin dose reductions (41% boceprevir and 42% telaprevir), 
although erythropoiesis-stimulating agent use was also common (40% boceprevir and 36% 
telaprevir). Blood transfusions were required in 10% of boceprevir-treated patients and in 
12% of those treated with telaprevir (Table 2). Among patients with HCV genotype 1, 
Multivariable logistic regression analysis was used to identify variables associated with 
anaemia, defined as haemoglobin <10 g/dl. The following variables were considered as 
potential baseline predictors of anaemia: creatinine clearance, platelets, haemoglobin, 
albumin total, bilirubin, HCV RNA level, gender, age, presence of cirrhosis, diabetes status, 
previous treatment experience, HCV subtype, and IL28B. Odds ratios adjusted for age and 
sex and their corresponding 95% confidence intervals are reported in Table 3. Age, female 
gender, the presence of cirrhosis, HCV subtype b, lower platelet levels (≤100,000/mm3), 
lower, albumin (<3.5 g/dl) and haemoglobin, and lower creatinine clearance were 
independent predictors of anaemia in the overall population. The odds of anaemia for 
women were 3 times the odds for men when controlling for age.
Among other adverse events designated of special interest, skin rash was reported most 
frequently by those treated with telaprevir (63%) compared to boceprevir (34%). Most 
rashes were mild, although serious rash was reported in 8 (<1%) of patients treated with 
telaprevir, including 2 with drug reaction with eosinophilia and systemic symptoms 
(DRESS), leading to premature treatment discontinuation. Anorectal symptoms were 
reported in 40% of those treated with telaprevir and 9% of those treated with boceprevir. 
Dysgeusia was noted in 4% and 13% of those treated with telaprevir and boceprevir, 
respectively. Three percent of patients, receiving either DAA, suffered a liver 
decompensation event.
An SAE occurred in 13% of patients on boceprevir and in 11% on telaprevir (Table 2). The 
most common reasons for SAE were anaemia (4%), infection (3%), and other causes (2%). 
Five patients, treated with a telaprevir-based regimen, died during the study (1 due to sepsis/
liver failure, 2 due to myocardial infarction, and 2 unspecified).
Impact of cirrhosis
Among the enrolled patients, 76 (4%) had a history of decompensation prior to the start of 
therapy as defined by the past medical history or the use of concomitant medications at 
baseline that were indicative of hepatic decompensation, including lactulose, rifaximin, 
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spironolactone, and furosemide. For beta blockers to be considered as indicative of hepatic 
decompensation it required an associated indication of bleeding from varices (not just 
prophylaxis). Among patients with a history of decompensation 33% experienced SAEs, 
83% suffered from anaemia, and 24% had a decompensation event. In these patients with a 
history of decompensation, the rate of premature treatment discontinuation was 59%, mostly 
due to AEs, compared to 47% of well-compensated cirrhotic patients. Logistic regression 
analyses noted that a lower baseline serum albumin level was associated with 
decompensation in both the telaprevir and boceprevir-treated populations when controlling 
for age and sex and that bilirubin level, platelet count, baseline HCV RNA levels and mean 
MELD score were predictive of liver decompensation in telaprevir patients, while the 
haemoglobin level was predictive of liver decompensation in those who received boceprevir 
(data not shown).
Discussion
This report describes the safety profiles of boceprevir and telaprevir in the largest and most 
diverse population treated for hepatitis C with these agents in the United States. We 
analysed the experiences of more than 2000 patients who were among the first U.S. patients 
to receive triple therapy at more than 100 medical centres. Our results demonstrate that 
patients treated in clinical practice with these agents were older and had more advanced 
disease than the registration trial participants, and were more likely to sustain significant 
adverse events. Overall SVR rates were slightly lower than those in registration trials.
More than 90% of patients had adverse events that led to a prescription, treatment, or dosage 
change; and more than one third of patients discontinued treatment early. Anaemia occurred 
in two thirds of patients and was the most clinically significant adverse effect. Despite a 
high rate of ribavirin dose reductions to manage anaemia, U.S. clinicians often used epoetin, 
an agent that was not permitted in the telaprevir registration trials, to treat anaemia. Indeed, 
nearly 40% of patients overall received epoetin alfa and a surprising 11% of patients 
required blood transfusions for treatment of severe anaemia. The rates of anaemia and 
treatment discontinuations in this analysis were far higher than reported for the pivotal 
registration studies of both boceprevir and telaprevir [2,3,7,10,11]. Interestingly, skin rash, 
more frequent among patients treated with telaprevir, had received much attention prior to 
the launch of telaprevir, although in the present study it was mostly of mild severity and was 
infrequently associated with DRESS or premature treatment discontinuation. This is likely 
due to increased vigilance and close monitoring, which prompted early intervention and 
minimized the progression of potentially serious skin reactions.
The reduced tolerability seen in this analysis is likely due to differences in patient 
populations in clinical studies compared to clinical practice. Relative to patients included in 
the registration trials, with enrolment starting in 2008, the patients in our analysis, starting in 
2011, were older, with a median age approximately 5 years higher and an upper range in 
their 70s vs. 60s [2,3,7,10,11] in the registration trials. More importantly, the patients in the 
present analysis received treatment at a more advanced stage of liver disease, with 38% 
having cirrhosis at baseline vs. the more typical 6–26% in the registration studies 
[2,3,7,10,11]. Further, more than half of the patients in our analysis had received prior 
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therapy for chronic HCV, thus indicating (a) an unmet need of a large proportion of prior 
non-responders to interferon-based therapies and (b) patient and clinician willingness to 
pursue additional and more intensive antiviral therapy than previously undertaken. The 
findings underscore the observation that the actual treated cohort in clinical practice 
represents a progressively older and histologically more advanced population than that 
reported in the pivotal registration trials.
Despite the large number of patients with cirrhosis, the rate of serious adverse events 
observed in our population (11% of patients receiving telaprevir and 13% receiving 
boceprevir) is very similar to that observed in the telaprevir (12%) and boceprevir (12%) 
registration trials in patients who had previously been treated [7,10], an observation that 
could be attributable to the attentive management of AEs. Liver disease was more severe 
among those with cirrhosis in the present HCV-TARGET analysis, as evidenced by lower 
platelet counts, a higher frequency of oesophageal varices, and the inclusion of numerous 
patients with evidence of prior decompensation, compared to two recent European reports of 
triple therapy in patients with advanced liver disease [8,12]. Indeed, the group of patients 
with a prior history of decompensation had the highest rates of AEs, SAEs, and premature 
treatment discontinuation. Of note, cure rates remained high even in those patients.
In the prospective analysis of 674 French patients with compensated cirrhosis in the CUPIC 
study, triple therapy was associated with a high incidence of serious adverse events (40%), 
as well as severe complications, such as severe infection or hepatic decompensation in 6.4%, 
and death in 1% of patients [6]. Severe anaemia occurred in 29%, although only 16% of 
patients had a ribavirin dose reduction, a rate lower than that reported in the present study 
where ribavirin dose reduction was the preferred intervention [6]. Erythrocyte stimulating 
agents were used in 51% of patients in the French study and 12% required blood 
transfusions. Deaths and severe complications were associated with lower platelet counts 
(≤100,000/μl) and lower albumin (<3.5 g/ dl) where the observed risk was 44% if patients 
had both features [9]. Comparable observations have been made from another European 
expanded access program that treated over 1500 patients with bridging fibrosis or 
compensated cirrhosis with protease inhibitor based therapy [8].
Although the standard of care for the treatment of HCV genotype 1 has shifted away from 
telaprevir and boceprevir containing regimens, the current study nevertheless has important 
implications for clinicians, particularly in regions outside of the U.S. where triple therapy 
with boceprevir or telaprevir, in combination with peginterferon and ribavirin, will remain 
the mainstay of therapy for the foreseeable future due to challenges with access to the most 
advanced therapies. This information is also of importance to health care policy researchers 
who will be comparing the effectiveness of multiple regimens across different populations.
The results of the present analysis indicate that HCV patients in clinical practice settings 
experience a greater potential for toxicity with boceprevir- or telaprevir-based triple therapy 
than patients who were selected for enrolment in the HCV drug development trials. The post 
marketing triple therapy experience in the U.S. mirrors the recent European experiences 
[6,8] and highlights a major disparity between the highly controlled HCV clinical trial 
experience and the real world reality of an aging, cirrhotic and medically more vulnerable 
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global HCV community. While there remains a lack of data for novel and less toxic 
therapies in patients with more advanced liver disease and co-morbidities, the present report 
underscores the need for a more inclusive patient population to be represented in future 
HCV clinical trials.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
Financial support
HCV-TARGET is an investigator-initiated study, jointly sponsored by The University of Florida, Gainesville, FL 
(PI: D.R. Nelson), and The University of North Carolina at Chapel Hill, Chapel Hill, NC (PI: M.W. Fried). It was 
funded in part by Vertex Pharmaceuticals, Inc., Merck & Co., Kadmon Corporation, and Genentech and in part by 
CTSA UF UL1TR000064 and UNC1UL1TR001111. M.W. Fried is funded in part by the NIH Mid-Career 
Mentoring Award K24 DK066144.
We thank the staff of the data coordinating center at UNC Chapel Hill: Lucy Akushevich, Kenneth Bergquist, John 
Baron, Paul Stewart, Dianne Mattingly, and Wendy Robertson; the staff of clinical coordinating center at UF 
Gainesville: Lauren Morelli, Anthe Hoffman, Dona-Marie Mintz, Lasheaka McClellan, Angela Bauer, Patrick 
Horne, Rennie Mills; the nurses and patients who were involved in this study; and Valérie Philippon, Ph.D. for her 
assistance in the preparation of the manuscript, with funding from University of Florida.
Abbreviations
HCV hepatitis C virus
DAAs direct-acting antiviral agents
PegIFNα pegylated interferon alfa
AE adverse event
SAE serious adverse event
SVR sustained virologic response
DRESS drug reaction with eosinophilia and systemic symptoms
References
1. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, et al. Efficacy of boceprevir, an 
NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive 
patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre 
phase 2 trial. Lancet. 2010; 376:705–716. [PubMed: 20692693] 
2. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for 
untreated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364:1195–1206. [PubMed: 
21449783] 
3. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. 
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 
364:2405–2416. [PubMed: 21696307] 
4. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al. 
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 
2009; 360:1827–1838. [PubMed: 19403902] 
Gordon et al. Page 9













5. Barritt AS, Fried MW. Maximizing opportunities and avoiding mistakes in triple therapy for 
hepatitis C virus. Gastroenterology. 2012; 142:1314–1323. [PubMed: 22537438] 
6. Hézode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, et al. Triple therapy in treatment-
experienced patients with HCV-cirrhosis in a multi-centre cohort of the French Early Access 
Programme (ANRS CO20-CUPIC) –NCT01514890. J Hepatol. 2013; 59:434–441. [PubMed: 
23669289] 
7. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for 
previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364:1207–1217. 
[PubMed: 21449784] 
8. Colombo M, Fernández I, Abdurakhmanov D, Ferreira PA, Strasser SI, Urbanek P, et al. Safety and 
on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis 
C. Gut. 2014; 63:1150–1158. [PubMed: 24201995] 
9. Maasoumy B, Port K, Markova AA, Serrano BC, Rogalska-Taranta M, Sollik L, et al. Eligibility 
and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world 
setting. PLoS One. 2013; 8:e55285. [PubMed: 23383319] 
10. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of 
HCV infection. N Engl J Med. 2011; 364:2417–2428. [PubMed: 21696308] 
11. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al. Response-
guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011; 
365:1014–1024. [PubMed: 21916639] 
12. Afdhal NH, Reau N, Everson GT, Morelli G, Lok AS, Kenneth E, et al. Safety and efficacy of 
telaprevir (TVR) or boceprevir (BOC) in Patients with cirrhosis: interim results of a longitudinal, 
observational study. Hepatology. 2013; 58:1103A–1104A.
Gordon et al. Page 10














Disposition of patients from enrolment to treatment initiation.
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Fig. 3. Haemoglobin levels
(A) Patients with haemoglobin levels ≥10 g/dl. (B) Patients with haemoglobin levels ≥8.5 
g/dl.
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Table 1
Baseline characteristics of patients.
Characteristics Boceprevir (n = 455) Telaprevir (n = 1629) Total (n = 2084)
Median age (range), yr 55 (20–77) 56 (18–75) 56 (18–77)
Male sex, n (%) 283 (62) 982 (60) 1265 (61)
Median BMI (range), kg/m2 28 (18–57) 28 (16–69) 28 (16–69)
Race, n (%)
 White 364 (80) 1281 (79) 1645 (79)
 Black 66 (15) 277 (17) 343 (16)
 Asian 13 (3) 33 (2) 46 (2)
 Other/missing 12 (3) 38 (2) 50 (2)
Ethnicity Hispanic,1 n (%) 28 (6) 103 (6) 131 (6)
Mean ALT (SD), mean IU/L 88 (81) 92 (78) 91 (79)
Mean total bilirubin (SD), mg/dl 0.7 (0.4) 0.8 (0.5) 0.8 (0.5)
Mean albumin (range), g/dl 4.1 (1.4–5.1) 4.0 (1.0–5.1) 4.1 (1.0–5.1)
Mean haemoglobin (SD), g/dl 15 (1.5) 15 (1.4) 15 (1.4)
Mean platelet count (range) (x103) per μl 182 (33–472) 173 (25–500) 175 (25–500)
History of cirrhosis,2 n (%) 140 (31) 648 (40) 788 (38)
History of esophageal varices,3 n (%) 56 (12) 213 (13) 269 (13)
History of liver decompensation, n (%) 12 (3) 56 (3) 68 (3)
Presence of diabetes, n (%) 79 (17) 224 (14) 303 (15)
IL28B genotype, n (%)
 CC 60 (13) 152 (9) 212 (10)
 CT, TT 142 (31) 393 (24) 535 (26)
 Unknown 253 (56) 1084 (67) 1337 (64)
HCV genotype, n (%)
 1a 254 (56) 914 (56) 1168 (56)
 1b 105 (23) 380 (23) 485 (23)
 1, subtype unspecified 86 (19) 286 (18) 372 (18)
 Other 10 (2) 49 (3) 59 (3)
Prior HCV treatment, n (%)
 Treatment-naïve 201 (44) 701 (43) 902 (43)
 Treatment-experienced 254 (56) 925 (57) 1179 (57)
 Unknown, multiple response 0 3 (<1) 3 (<1)
 HCV RNA ≥800,000 IU/ml, n (%) 321 (71) 1150 (71) 1471 (71)
ALT, alanine aminotransferase; HCV, hepatitis C virus.
1
Data available on 2064 patients.
2
Data available on 2045 patients.
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3
Data available on 794 patients.
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Table 2
Patient disposition, sustained virologic response, safety profile, and anaemia management.
Boceprevir (n = 455) Telaprevir (n = 1629) All patients (n = 2084)
Patient disposition during treatment, n (%)
 Completed therapy 255 (56) 989 (61) 1244 (60)
 Discontinued early 200 (44) 621 (38) 821 (39)
  Adverse event 83 (18) 290 (18) 373 (18)
  Lack of efficacy 89 (20) 255 (16) 344 (17)
  Lost to follow-up 22 (5) 48 (3) 70 (3)
  Other 6 (1) 28 (2) 34 (2)
 No EOT data 0 19 (1) 19 (<1)
Sustained virologic response, n (%, 95% CI) 200 (44, 39–49) 883 (54, 52–57) 1083 (52, 50–54)
Adverse events, n (%) 422 (93) 1561 (96) 1983 (95)
 Anaemia 310 (68) 1056 (65) 1366 (66)
 Rash 155 (34) 1026 (63) 1181 (57)
 Anorectal symptoms 43 (9) 648 (40) 691 (33)
 Infection 78 (17) 242 (15) 320 (15)
 Dysgeusia 57 (13) 65 (4) 112 (6)
 Decompensating event 12 (3) 56 (3) 68 (3)
Serious adverse events, n (%) 57 (13) 183 (11) 240 (12)
 Anaemia 18 (4) 57 (3) 75 (4)
 Infection 14 (3) 43 (3) 57 (3)
 Other 8 (2) 29 (2) 37 (2)
 Decompensation 3 (<1) 13 (<1) 16 (<1)
 Rash 0 8 (<1)* 8 (<1)
 Anorectal symptoms 0 7 (<1) 7 (<1)
 Dysgeusia 0 0 0
Haemoglobin decline, n (%)
 Haemoglobin <10 g/dl 236 (52) 812 (50) 1048 (50)
 Haemoglobin <8.5 g/dl 69 (15) 285 (17) 354 (17)
Anaemia management, n (%)
 Ribavirin dose reduction 188 (41) 686 (42) 874 (42)
 Epoetin use 182 (40) 580 (36) 762 (37)
 Blood transfusion 44 (10) 193 (12) 237 (11)
 Ribavirin interruptions 16 (4) 41 (3) 57 (3)
Deaths, n 0 5 5
*
SAE rash included 2 patients with DRESS.
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